The export of innovation to China

The latest company to establish a large research facility in China comes from the drugs industry, one of the sectors which has been the least aggressive in off-shoring to low-cost labour destinations.

by Financial Times
Last Updated: 23 Jul 2013

Now, AstraZeneca has announced its intentions to invest $100m in a research facility in China, focusing on the relationship between cancer and genetics in Chinese patients. The centre, which is likely to be built in Shanghai in 2009, will also be used to create links with academic research centres in China.

Other pharma companies which have already set up research facilities in China include Novo Nordisk, Eli Lilly and Pfizer. The trend in China has been matched by similar developments in India, where both AstraZeneca and GlaxoSmithKline have research connections.

The question of which country is the best one to invest in – China or India – is being hotly debated in the pharmaceutical sector.

Source:
AZ to invest $100m in Chinese Research
Financial Times, May 27/May 28 2006
Review by Morice Mendoza

Financial Times recommends

Financial Times

Read more

Find this article useful?

Get more great articles like this in your inbox every lunchtime

Has the cult of workplace wellbeing run its course?

Forget mindfulness apps and fresh fruit Fridays. If we really care about employee wellbeing, we...

Cybercriminals: A case study for decentralised organisations?

A study shows that stereotypes of organised criminals are wide of the mark.

Why your turnaround is failing

Be careful where you look for advice.

Crash course: How to find hidden talent

The best person for the role might be closer than you think.

What they don't tell you about flexible working

The realities of ditching the nine to five don't always live up to the hype....

The business case for compassion: Nando's, Cisco and Innocent Drinks

Consciously, systematically humane cultures reap enormous benefits, argues academic Amy Bradley.